In 1977, a British epidemiologist named Richard Peto pointed out something that should have been obvious and wasn't. If cancer is caused by mutations in dividing cells, and every cell division carries a small chance of mutation, then large animals with longer lives should get far more cancer than small ones. A blue whale has roughly a thousand times more cells than a human. A whale that lives a century should, by this logic, develop cancer almost inevitably — the accumulated risk should guarantee it.
It doesn't. Whales get cancer at rates comparable to humans. Elephants, with their hundred-fold cell advantage, don't have cancer wards. This became known as Peto's paradox: at the species level, body size and cancer risk are basically unrelated. The math predicts a curve that doesn't exist.
What makes it sharper: within a species, the prediction holds. Taller humans have modestly higher cancer rates than shorter ones. The relationship is real, it just disappears when you zoom out. Large animals evolved something to compensate.
The question was what. The answer, it turns out, is different for each animal.
Elephants have twenty copies of TP53 in their genome. Humans have one. TP53 encodes a protein called p53, sometimes called the "guardian of the genome" — when a cell's DNA is damaged badly enough, p53 triggers apoptosis: the cell kills itself before it can replicate the error. In elephants, this system is hair-trigger sensitive. Studies of elephant lymphocytes show they undergo apoptosis at dramatically higher rates than human cells when exposed to the same DNA-damaging treatments. More copies mean lower threshold: when damage occurs, the cell doesn't try to repair it, it just dies. The extra copies appeared gradually in the fossil record as elephants grew larger, which makes the story tidier than most evolutionary stories get.
Naked mole rats took a different approach. They're not large — about 30 grams — but they live nearly thirty years, ten times longer than other rodents of similar size, and cancer in their colonies is almost unheard of. Vera Gorbunova's lab at Rochester spent years looking for the mechanism and found it in 2013: an unusual form of hyaluronan, a molecule that coats the space between cells. Naked mole rat hyaluronan is over five times larger than the human version, and it accumulates thickly in their tissues. When cells start to crowd together — an early precondition for tumor growth — the high-molecular-mass hyaluronan signals them to stop dividing. Contact inhibition, the normal brake on cell growth, is massively amplified. Gorbunova's team confirmed this by disabling the gene responsible: take away the unusual hyaluronan, and naked mole rat cells become susceptible to malignant transformation like any other cell. The molecule appears to have evolved originally for skin elasticity — naked mole rats spend their lives pushing through underground tunnels, and flexible skin is a practical advantage. Cancer resistance was a side effect of solving a different problem.
Bowhead whales, which live two centuries and are the largest of the three, seem to use a third approach: better repair rather than faster killing or earlier prevention. Research published in 2025 found that bowhead whale cells show enhanced capacity to fix double-strand DNA breaks — one of the most dangerous types of damage — and lower baseline mutation rates than other mammals. The key appears to be a protein called CIRBP, cold-inducible RNA-binding protein, which is highly expressed in bowhead tissues. When researchers inserted the bowhead version of CIRBP into human cells, those cells showed improved DNA repair. Expressing it in fruit flies extended their lifespan and improved radiation resistance. The bowhead's strategy is to not let errors accumulate in the first place, rather than catching them downstream.
Three animals, three evolutionary lineages, three approaches to the same problem. Elephants cull damaged cells aggressively. Naked mole rats block the path to tumor growth upstream. Whales repair more faithfully. None of them are doing the same thing.
What I keep coming back to is the shape of the discovery process. Peto's paradox existed as a statistical fact for decades before anyone identified mechanisms. The paradox was the signal — something is suppressing cancer in large animals, we just don't know what — and following the signal produced different findings in different animals. The asking was general; the answers were specific. Each species found a different door.
There's an open question behind all of this that I don't think anyone has resolved: why didn't large animals converge on a single solution? Convergent evolution happens routinely — wings in birds, bats, and pterosaurs, echolocation in bats and dolphins. The problem of cancer suppression is the same problem in every large-bodied lineage. Yet elephants, naked mole rats, and whales each found something different. Maybe the solution space is wider than it looks. Maybe what worked depended on what was already there. Or maybe we're looking at three stops on a longer continuum of mechanisms we haven't cataloged yet. The paradox isn't fully dissolved — it's just been opened up from one question into several.